Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -12.76% and Operating profit at -28.47% over the last 5 years
2
The company has declared Positive results for the last 4 consecutive quarters
3
With ROE of 7.13%, it has a very attractive valuation with a 1.37 Price to Book Value
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 1,805 Million (Small Cap)
13.00
NA
0.00%
-0.58
3.58%
0.47
Revenue and Profits:
Net Sales:
195 Million
(Quarterly Results - Mar 2026)
Net Profit:
19 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-34.63%
0%
-34.63%
6 Months
-36.02%
0%
-36.02%
1 Year
-37.99%
0%
-37.99%
2 Years
-15.32%
0%
-15.32%
3 Years
-21.09%
0%
-21.09%
4 Years
-67.52%
0%
-67.52%
5 Years
-71.18%
0%
-71.18%
Hangzhou Alltest Biotech Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-8.03%
EBIT Growth (5y)
-31.00%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.64
Sales to Capital Employed (avg)
0.21
Tax Ratio
12.48%
Dividend Payout Ratio
71.47%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
143.79%
ROE (avg)
16.57%
Valuation key factors
Factor
Value
P/E Ratio
13
Industry P/E
Price to Book Value
0.47
EV to EBIT
-2.94
EV to EBITDA
-2.34
EV to Capital Employed
-0.26
EV to Sales
-0.48
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
3.58%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Bearish
Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
195.40
272.30
-28.24%
Operating Profit (PBDIT) excl Other Income
28.70
34.50
-16.81%
Interest
0.20
0.10
100.00%
Exceptional Items
5.60
21.70
-74.19%
Consolidate Net Profit
19.10
30.30
-36.96%
Operating Profit Margin (Excl OI)
146.90%
76.00%
7.09%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -28.24% vs 34.01% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -36.96% vs -47.40% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
902.20
861.60
4.71%
Operating Profit (PBDIT) excl Other Income
222.60
282.50
-21.20%
Interest
2.10
1.90
10.53%
Exceptional Items
40.60
38.70
4.91%
Consolidate Net Profit
220.10
302.90
-27.34%
Operating Profit Margin (Excl OI)
194.90%
279.00%
-8.41%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 4.71% vs 15.23% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -27.34% vs 68.00% in Dec 2024
About Hangzhou Alltest Biotech Co., Ltd. 
Hangzhou Alltest Biotech Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






